File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Serotonergic antagonists and vascular disease

TitleSerotonergic antagonists and vascular disease
Authors
Issue Date1990
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0920-3206
Citation
Cardiovascular Drugs And Therapy, 1990, v. 4 SUPPL. 1, p. 7-12 How to Cite?
Abstract5-Hydroxytryptamine (serotonin) can evoke both contraction and relaxation of vascular smooth muscle. In disease, the constrictor component of the response to the monoamine appears to dominate. 5HT2-serotonergic antagonists favor dilatation, not only because they block the activating effect of serotonin on vascular smooth muscle, but also because they unmask the (endothelium-dependent) relaxation to the monoamine and brake the amplifying effect that it exerts on platelet aggregation. These properties of serotonergic antagonists help to explain their protective effects in vascular disease.
Persistent Identifierhttp://hdl.handle.net/10722/173476
ISSN
2015 Impact Factor: 3.189
2015 SCImago Journal Rankings: 1.114
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:32:15Z-
dc.date.available2012-10-30T06:32:15Z-
dc.date.issued1990en_US
dc.identifier.citationCardiovascular Drugs And Therapy, 1990, v. 4 SUPPL. 1, p. 7-12en_US
dc.identifier.issn0920-3206en_US
dc.identifier.urihttp://hdl.handle.net/10722/173476-
dc.description.abstract5-Hydroxytryptamine (serotonin) can evoke both contraction and relaxation of vascular smooth muscle. In disease, the constrictor component of the response to the monoamine appears to dominate. 5HT2-serotonergic antagonists favor dilatation, not only because they block the activating effect of serotonin on vascular smooth muscle, but also because they unmask the (endothelium-dependent) relaxation to the monoamine and brake the amplifying effect that it exerts on platelet aggregation. These properties of serotonergic antagonists help to explain their protective effects in vascular disease.en_US
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0920-3206en_US
dc.relation.ispartofCardiovascular Drugs and Therapyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshHumansen_US
dc.subject.meshSerotonin Antagonists - Therapeutic Useen_US
dc.subject.meshVascular Diseases - Drug Therapy - Physiopathologyen_US
dc.titleSerotonergic antagonists and vascular diseaseen_US
dc.typeConference_Paperen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00053420-
dc.identifier.pmid2285653-
dc.identifier.scopuseid_2-s2.0-0025217279en_US
dc.identifier.volume4en_US
dc.identifier.issueSUPPL. 1en_US
dc.identifier.spage7en_US
dc.identifier.epage12en_US
dc.identifier.isiWOS:A1990CW23000002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats